EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC

February 11, 2019 5:45 PM
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles